Zai Lab’s Robust Product Growth and Portfolio Expansion Drive Buy Recommendation
Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...
Impacts7 天
Meet Srinivasa Reddy Mukkala, The Multidisciplinary Expert Transforming Gene Therapy ...
Few fields in medicine are as promising and complex as gene therapy. As researchers race to develop cures for previously ...
Pharmaceutical Technology19 天
Omadacycline tosylate by Paratek Pharmaceuticals for Osteomyelitis: Likelihood of Approval
Omadacycline tosylate is under clinical development by Paratek Pharmaceuticals and currently in Phase I for Osteomyelitis. According to GlobalData, Phase I drugs for Osteomyelitis have a 100% phase ...
Pharmaceutical Technology20 天
ZL-1102 by Zai Lab for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
ZL-1102 is under clinical development by Zai Lab and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) ...
University of Houston1 年
A New Weapon Against the Super Tough C Diff Bacteria
In a phase-one human clinical trial, a University of Houston pharmacist researcher has demonstrated that a newer generation tetracycline antibiotic, called Omadacycline, may be a promising tool in ...